Kaken Pharmaceutical Co., Ltd. (TYO:4521)
Japan · Delayed Price · Currency is JPY 3,785.00
-15.00 (-0.39%)
Jun 19, 2026, 3:30 PM JST
Kaken Pharmaceutical Stock Forecast
Stock Price Forecast
According to 4 analysts polled by S&P Global, Kaken Pharmaceutical stock has a consensus rating of "Hold" and an average price target of ¥4,325. The average 1-year stock price forecast is 14.27% higher than the current stock price, while the lowest is ¥3,600 (-4.89%) and the highest is ¥5,200 (+37.38%).
Price Target: ¥4,325 (+14.27%)
Analyst Consensus: Hold
* Price targets were last updated on Dec 12, 2025.
Analyst Ratings
The average analyst rating for Kaken Pharmaceutical stock is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 1 | 1 | 1 | 1 | 1 | 1 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
Mark Yokoyama UBS No rating | UBS | Hold Initiates ¥4,200 | Hold | Initiates | ¥4,200 | +10.96% | Dec 12, 2025 |
Financial Forecast
Revenue This Year
79.65B
from 76.87B
Increased by 3.61%
Revenue Next Year
81.42B
from 79.65B
Increased by 2.22%
EPS This Year
n/a
EPS Next Year
n/a
Financial currency is JPY.
Revenue Forecast
| Revenue | 2027 | 2028 | 2029 |
|---|---|---|---|
| High | 89.0B | ||
| Avg | 79.6B | ||
| Low | 73.3B |
Revenue Growth
| Revenue Growth | 2027 | 2028 | 2029 |
|---|---|---|---|
| High | 15.8% | ||
| Avg | 3.6% | ||
| Low | -4.6% |
EPS Forecast
| EPS | 2027 | 2028 | 2029 |
|---|---|---|---|
| High | - | ||
| Avg | - | ||
| Low | - |
EPS Growth
| EPS Growth | 2028 | 2029 |
|---|---|---|
| High | - | |
| Avg | - | |
| Low | - |